Calamagrostis arundinacea Extract Mitigates Testosterone Induced Prostatic Hyperplasia in Rats
Pharmaceuticals · 11.03.2026 · 19 (3) · 453
DOI: 10.3390/ph19030453 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 11.03.2026. Verfasst von Poornima Kumbukgahadeniya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Republic of Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported by the BK21 FOUR Program by Chungnam National University Research Grant, 2024..
Abstract (Originalsprache)
Background
Benign prostatic hyperplasia (BPH) is an age-associated urological condition defined by abnormal multiplication of both stromal and epithelial components within the prostate. Calamagrostis arundinacea (CA), a species of perennial grass native to East Asia, has been recognized for its anti-inflammatory and antioxidant biological activities. The present study examined whether CA extract could attenuate prostatic enlargement induced by testosterone propionate (TP) in rats. Methodology: To establish the experimental model, rats received subcutaneous TP injections (3 mg/kg/day) for four consecutive weeks. During the same period, an extract of CA (150 mg/kg/day) was orally administered.
Results
TP-treated animals developed significant prostatic enlargement, whereas CA supplementation markedly reduced prostate weight and significantly decreased circulating dihydrotestosterone (DHT) and testosterone levels. Microscopic analysis demonstrated that CA mitigated glandular epithelial thickening and suppressed hyperplastic alterations. In addition, CA reduced proliferating cell nuclear antigen (PCNA) expression and increased apoptotic cell numbers, as evidenced by TUNEL staining. Gene expression analysis further revealed significant downregulation of insulin-like growth factor-2 (Igf-2), transforming growth factor-β (Tgf-β), and vascular endothelial growth factor (Vegf), in CA-treated prostates. Moreover, CA inhibited activation of the PI3K/Akt/mTOR signaling cascades by reducing phosphorylation of Akt and mTOR.
Conclusions
Overall, these results indicate that CA extract alleviates testosterone-induced BPH through suppression of growth-related signaling cascades and induction of apoptosis, suggesting its potent value as a phytotherapeutic strategy for BPH management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
- Department of Physiology, College of Medicine, Jeju National University, Jeju-si 63243, Republic of Korea.
- Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju-si 28116, Republic of Korea.
ORCID-Profile: Eun-Bok Baek, Won-Kee Yoon
Förderung
- This work was supported by the BK21 FOUR Program by Chungnam National University Research Grant, 2024.
Zitieren
APA
Kumbukgahadeniya, P., Baek, E. B., Lee, S. H., Ha, D. I., Hong, E. J., Song, J. Y., Yoon, W. K., & Kwun, H. J. (2026). Calamagrostis arundinacea Extract Mitigates Testosterone Induced Prostatic Hyperplasia in Rats. Pharmaceuticals, 19(3), 453. https://doi.org/10.3390/ph19030453
Vancouver
Kumbukgahadeniya P, Baek EB, Lee SH, Ha DI, Hong EJ, Song JY, et al. Calamagrostis arundinacea Extract Mitigates Testosterone Induced Prostatic Hyperplasia in Rats. Pharmaceuticals. 2026;19(3):453. doi:10.3390/ph19030453
BibTeX
@article{Kumbukgahadeniya2026,
author = {Kumbukgahadeniya, Poornima and Baek, Eun-Bok and Lee, Seung-Hoon and Ha, Dae-In and Hong, Eun-Ju and Song, Jun-Yeop and Yoon, Won-Kee and Kwun, Hyo-Jung},
title = {Calamagrostis arundinacea Extract Mitigates Testosterone Induced Prostatic Hyperplasia in Rats},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {3},
pages = {453},
doi = {10.3390/ph19030453}
}
EUVIMED